I n t r o d u c t i o n : The adrenal glands are paired and located in the retroperito� The adrenal glands are paired and located in the retroperito� neal space, above the upper pole of the kidney. Adrenal tumors depending on the histopathological structure, may be divided into: epithelial, mesenchymal, lymphoid and adrenal medulla tumors. Depending on the etiology, distingu� ishes between tumors, inflammatory tumors, true adrenal cysts, pseudocysts and parasitic adenomas and proliferative processes. The adrenal incydentaloma is a pathological tissue in the adrenal gland, with a diameter of ≥ 1 cm, diagnosed during diagnostics for reasons other than adrenal pathology.
INTRODUCTION
The adrenal glands are the endocrine glands, the paired, located in retroperitoneal space, above the upper pole of the kidney, within its adipose capsule. The adrenal glands are made of peripheral bark, taking up approximately 80%-90% of the organ and core, in the central part of the gland. The right adrenal gland is triangular in shape, lo� cated to the back of the liver, medially to the inferior vena cava. The left adrenal gland is slightly more round, it is lo� cated backwards from the stomach, from which the lesser sac separates them. 1 Adrenal tumors can come from both layers of normal adrenal glands. The division of adrenal tumors, depending on the histopathological structure, is presented in Table 1 . [2] [3] [4] [5] [6] [7] Depending on the etiology among adrenal tumors, we distinguish between tumors (primary and metastatic), in� flammatory (tuberculosis, sarcoidosis, histoplasmosis), true adrenal cysts, pseudocysts, parasitic adrenal cysts and pro� liferative processes that are characterized by microademic hyperplasia, macrogyal adrenal glands or are observed in patients with congenital adrenal hyperplasia (CAH). 3, 8 Adrenal incidentaloma (AI) is a pathological tissue mass in the adrenal gland, at least 1 cm in diameter, diagnosed during diagnostics for reasons other than suspected adrenal pathology. 4, 9, 10 AI diagnosis excludes focal lesions depicted during the diagnostics of hormone�dependent hyperten� sion or active cancerous disease. 11 AI are asymptomatic in 70%-94%, benign adenomas, without hormonal activity. The adrenal carcinoma is rarely diagnosed, in about 2%-4% of patients. The risk of cancer increases with the size of the tumor. In tumors up to 4 cm the risk is about 2%. When the diameter of the cancerous change exceeds 6 cm, the risk of malignancy increases up to 25%. 2, 12 In the available litera� ture, 2.5 times more frequent occurrence of AI in women in life�related studies is noticed, whereas in post�mortem examinations there are no such differences. 13, 14 These dif� ferences are probably related to the fact that women more often and more willingly submit to available imaging ex� aminations. In addition to primary adrenal cancers, the incidentalomas may be metastatic, most commonly kidney cancer, lungs, liver, less often of colon, stomach, breast and melanoma. 11 AI may also be inflammatory or granulomatous changes in the course of tuberculosis or histoplasmosis, he� matomas, cysts, lipomas, liposarcoma, schwannomas or may occur in persons with CAH. 2,4,13
AIM
The increasing availability of ultrasonography (USG) and computed tomography (CT) imaging has made adrenal tu� mors a increasing clinical problem. Previously, adrenal tu� mors were diagnosed in 1.4%-6.0% of post�mortem exami� nations, and currently they are diagnosed in approximately 0.4% of people in abdominal ultrasound scan examinations and in 2%-4% of CT studies. 15 The work aims to discuss the available diagnostic and therapeutic methods of AI.
MATERIAL AND METHODS
The paper was based on the available literature of the sub� ject, magazines and the latest guidelines (MEDLINE lit� erature search). The search was conducted using the term 'adrenal incidentaloma'.
DISCUSSION

Methods for diagnosing adrenal tumors
USG is the most available, often first, study that shows the adrenal tumor. The ultrasound scan examination also re� veals possible necrosis, calcifications or cysts in the tumor. It is the method of choice for further periodic check�ups in people who were excluded from hormonal and oncological indications for surgery. Due to the anatomical position, the left adrenal glands are more difficult to assess in the ultra� sonography than the right adrenal glands. Tumors of about 2 cm are already well visible on both sides in this imaging method, while smaller ones are mainly seen in the right ad� renal glands. 15 CT without or with intravenous contrast evaluated after 1 and 10 minutes is a test that verifies ultrasound scan, and also the most useful for the assessment of adrenal tumor. A CT scan without contrast is the first-line examination in the diagnosis of adrenal tumors, relatively cheap. The CT ex� amination with the use of contrast agent aims to accurately assess focal lesions inconclusive in CT studies without any contrast medium ( Table 2) . [16] [17] [18] Nuclear magnetic resonance (NMR) performed in phase and antiphase with the assessment of tumor size, location and phenotype can be a complementary examination of CT, es� pecially in cases of suspected pheochromocytoma or adreno� cortical carcinoma. The NMR study differentiates adenomas from the so�called non�adenomas. This study is recommend� ed for pheochromocytoma and paraganglioma (PPGL) as� sociated with suspicion of metastases, cranial and neck basal paraganglioma, in patients with surgical clips that may be a source of artifacts in CT, pregnant women, children, people with a known germline mutation, as well as patients who have a history of sensitization to iodine contrast agents used during CT and those exposed lately to ionizing radiation. 17, 19 Positron emission tomography (PET) with 18-fluorode� oxyglucose (FDG) input is used in the diagnosis of adrenal cortex cancer and metastatic changes. 20 Adrenal scintigraphy using 131I�6�beta�iodomethyl� 19-norcholesterol iodine cholesterol analogs (NP-59) is a test useful in the diagnosis of Cushing's syndrome or, more rarely, primary hyperaldosteronism, to differentiate adenoma and ad� renal hyperplasia. 20 Adrenal scintigraphy with the use of 123I metaiodobenzylguanidine (MIBG) is characterized by high sensitivity and specificity in the detection of pheochromocy� tomas, including those located out of adrenal. 16 A fine-needle aspiration biopsy (FNAB) is performed under the control of CT. FNAB is currently rarely performed due to the high risk of complications such as: pneumothorax, kidney or liver haemor� rhage. FNAB is performed mainly when suspected metastatic tumor with an unknown starting point or adrenal tuberculosis. The study is contraindicated in case of suspected adrenocorti� cal cancer due to the risk of tumor spread and pheochromocy� toma due to catecholamine crisis. 10, 16, 21 Hormonal diagnosis is presented in Table 3 . 6, 9, 10, 19, [22] [23] [24] In the diagnostics of adrenal tumors, biochemical tests such as peripheral blood morphology, fasting blood serum, lipid profile, serum sodium, potassium and diurnal potas� sium excretion in the blood are also assessed. 9,10
Adrenal hormone -active tumors
Phaeochromocytoma is a tumor originating from pheochro� mocytomas, most often the adrenal medulla (adrenal loca� tion is almost 90% of cases), usually producing adrenaline and norepinephrine, and less frequently dopamine. It oc� curs in 0.1% of patients with hypertension and in about 5% of patients with AI. 19, 25 Typical symptoms associated with excessive secretion of catecholamines produced by pheo� chromocytomas are paroxysmal increases in blood pressure, often alternating with hypotension, orthostatic hypoten� sion, tachycardia, excessive sweating, paleness of the skin, headaches. An unrecognized, clinically silent pheochromo� cytoma may be the cause of hypertensive crisis in patients undergoing surgery, after CT or during, and also during other medical procedures, therefore a diagnosis of pheo� chromocytoma is required in each patient with AI. 25 Adrenocorticotropic hormone (ACTH)-independent Cushing's syndrome is caused by primary excessive pro� duction of cortisol by adrenocortical tumors, in patients with bilateral adrenal corticosteroid or McCune-Albright syndrome, it occurs in 15%-20% of people. [25] [26] [27] [28] Autonomic secretion of cortisol should be suspected in patients with AI and obesity, newly diagnosed or unstable hypertension, diabetes and osteoporosis. 29 Patients diagnosed after detec� tion of an AI has milder hypercortisoluria than patient with ACTH-dependent Cushung's syndrome, and patient with smaller AI receive post�adrenalectomy glucocorticoid treat� ment for shorter periods. 30 Hormonal diagnosis is important because subclinical hy� percortisolism may increase mortality of these people due to cardiovascular diseases and increase the risk of developing diabetes. 31, 32 It should be remembered that this group of pa� tients may never develop a full-blown Cushing's syndrome. 29 For asymptomatic AI, the morning cortisol concentration in the dexamethasone 1 mg inhibition test over 3.4 μg/dL was determined as requiring further hormonal diagnosis for hy� percortisolemia (97% sensitivity and 88% specificity in the diagnosis of hypercortisolemia). 9, 31 In case of diagnostic un� certainty, a corticotropin releasing hormone (CRH) test can be performed, or again a test with 1 mg dexamethasone or a 48�hour dexamethasone 2�mg inhibition test with a morn� ing cortisol score after the test. 23, 27 Subclinical hypercortisolism or subclinical Cushing's syndrome, according to the latest guidelines of the Euro� pean Society of Endocrinology (ESE), autonomic secretion of cortisol is the most frequently diagnosed hormonal disor� der in AI and constitutes 5%-8%. 10, 16, 25, 33 These patients do not have the typical clinical features of Cushing's syndrome, but only some of its clinical and biochemical abnormalities: hypertension, abdominal obesity, carbohydrate metabolism disorders, dyslipidemia and decreased bone mass. Labora� tory tests in this group of patients indicate: disturbed circa� dian rhythm of cortisol (elevated morning cortisol with in� Low lipid adenoma -density not more than 10 jH
Suspected malignancy / pheochromocytoma of the adrenal gland -native density over 10 jH
After the contrast injection, significant change in intensity at 1 and 10 minutes; quick rinsing of the contrast to a value of at least 50% of the maximum value -suggestion of benign change, delayed contrast rinsing with leach rate less than 50% associated with pathological vascularization -suggestion of malignant or pheochromocytoma; lack of increased densities after contrast agent injection -cysts and hematomas
Benign tumors -homoge� neous lesions
Malignant lesions / pheo� chromocytoma -foci of decay sufficient reduction of nocturnal cortisol), reduced morning ACTH concentration (<5 pg/mL), increase in circulatory excretion of free cortisol in urine or 17-OHCS at the up� per limit of the laboratory standard and suppression in the desamethasone 1 mg inhibition test over 1.8 g/dL. 9, 29 Some studies have shown that the cortisol and ACTH ratio at 0:00 has better the diagnostic performance than nocturnal corti� sol and may be a reliable parameter for subclinical hypercor� tisolism screening in patient with AI. 34 Primary hyperaldosteronism (Conn syndrome) is a group of disorders resulting from inadequately high levels of aldos� terone. Conn syndrome occurs in 1.6%-3.3% of people with AI, in about 10% of patients with refractory hypertension, latent Conn syndrome is observed in about 1%-5% of peo� ple with AI and less than 1% in the general population. 10, 35 According to ESE recommendations, all patients with hyper� tension and incidentaloma should be screened for primary hyperaldosteronism. 22, 31, 32 Given that the diagnosis of prima� ry aldosteronism is time consuming, costly, and tricky and necessitates specialized clinicians, laboratories, and centers, a more appropriate selection of candidates for screening should be preferred. 36 Adrenal tumors with excessive secretion of androgens. Excessive production of androgens by the adrenal glanddehydroepiandrosterone sulphate (DHEAS) and andros� tendione, is manifested by hirsutism in women, baldness in androgen�dependent regions and severe acne. Subclinical excess of androgens in AI patients occurs in about 1% of people. Significant androgenization, especially associated with hypercortisolemia, in patients with adrenal tumor sug� gests the diagnosis of adrenal cortex cancer, therefore the androgens listed are malignant markers. 2   Table 3 . Hormonal diagnosis.
Hormonal tests Description
ACTH concentration in the blood serum in the circadian rhythm
The most important is the morning ACTH concentration determined until 9:00.
Cortisol concentration in the circadian rhythm Between 6:00 and 8:00, 22:00 and 24:00 in the blood serum.
Late�night cortisol concentration in saliva
Clearly reflects the concentration of free cortisol (not related to proteins), determined between 22:00 and 24:00 (available in a few centers in the country).
Dexamethasone suppression tests 1. Morning cortisol levels were assessed in serum after administration of 1 mg dexamethasone between 22:00 and 23:00. 2. Morning cortisol in the test with a dose of 2 mg dexamethasone determined after the 2nd day of the test; is performed with intake of 0.5 mg dexamethasone every 6 hours orally for 2 days or with 2 mg dexamethasone once between 22:00 and 23:00 with the assessment of morning corti� sol the next day.
The dexamethasone 8 mg test (Liddle test)
is performed by giving 0.5 mg dexamethasone every 6 hours orally for 2 days followed by 2 mg dexamethasone every 6 hours orally for the next 2 days of the test.
The test requires a 24�hour urinary excretion of free cortisol before the test, on days 2 and 4 of the test.
Inhibition tests with more than 1 mg dose of dexamethasone are performed after exclusion of the adrenal phaeochromocytoma.
Daily excretion of free cortisol in urine and/or diurnal excretion of 17�hydroxycorticosteroids in urine (17-OHCS)
-PRA Determined for the purpose of calculating the aldosterone/PRA index. PRA is measured in the morning after nighttime rest and in dynamic tests: after orthostatic posture, with furosemide (agents stimulating the release of renin). The PRA value is influenced by the time of day, the position of the body before the examination and the diet.
Serum aldosterone concentration
After nocturnal sleep and in dynamic tests (diet with high sodium content, intravenous infusion of 0.9% NaCl, fludrocortisone, captopril (aldosterone suppressants). It should be remembered that aldosterone and PRA concentrations are the effect of the time of day, the position of the body before the examination and diet.
Concentration of DHEAS in serum
Independent of the time of day, but depending on the sex and age of the patient.
Serum androstenedione concentration
Dependent on sex, time of day and phase of menstrual cycle in women; usually high concentra� tions are observed in adrenal cortex cancer.
Concentration of 17�alpha�hydroxyprogesterone (17OHP) in serum
Depending on the phase of the menstrual cycle in women.
Plasma chromogranin A concentration -
Plasma concentrations of metanephrines: metanephrine, normetanephrine and 3�methoxythrine
Concentrations of metanephrines excreted with urine in at least two 24�hour urine collections. Concentration of metanephrins in serum and urine is always determined after a special 3�day elimination diet and pharmacological modification of treatment of hypertension (only alpha-blocker�doxazosin and/or calcium channel blocker verapamil are used before testing metaneph� rins in serum or urine) Comments: PRA -plasma renin activity; DHEAS -dehydroepiandrosterone sulphate 4.3. Medical treatment in people with AI Treatment in patients with incidentaloma is based on inter� views, physical examination, tumor phenotype in CT (size, native and contrast density) and tumor hormonal activity. 10 The influence of administered medications, age and con� comitant diseases must be taken into account when inter� preting test results. 37 The indications for surgical treatment of patients with adrenal tumors are presented in Table 4 . 9, 10, 38 In patients with hormonal active adrenal gland tumors, pharmacological preparation of the patient for adrenalec� tomy is necessary. 39 In the case of a pheochromocytoma, treatment of at least 2 weeks with an alpha�blocker is rec� ommended, and if it is a patient with persistent tachycar� dia, the addition of a beta�blocker. 17 In patients diagnosed with Conn syndrome, aldosterone antagonists -spironol� actone or eplerenone -are used a few weeks before adrenal� ectomy. 23 Patients with Cushing's syndrome require treat� ment with ketoconazole or metyrapone for 3-4 weeks. 24 In patients with tumors up to 6-8 cm, surgical treatment of the adrenal tumor is performed using the laparoscopic method, in the case of tumors more than 6-8 cm or on� cological indications, classical surgical approach is used. 38 There is no consensus as for AI smaller than 40 mm and hormonally inactive. 40
Preservative proceedings in people with AI
Individuals with normal tumor hormonal activity and tu� mor diameter not exceeding 4-5 cm, in CT examination with native densities of negative values or not exceeding 10 jH, with high contrast rinsing coefficient (>50%), are subjected to clinical observation. Hormonal and imaging examina� tions are performed every 6 months, and after 2 years once a year. 9, 10 There is no consensus regarding long�term observa� tion of patients with AI and normal hormonal activity who have not undergone surgical treatment, however according to the guidelines of the Polish Endocrinological Society 'if the change in the adrenal gland does not raise oncological anxiety and does not increase in subsequent imaging studies, you can stop the control after 4 years. In further observation, the risk of transformation to malignancy is close to zero.' 9 A similar position was accepted by the ESE and confirmed on retro� spective cohort study. 31, 41 Recommendations of the Polish Endocrinological Soci� ety, apart from monitoring in imaging, are also recommend� ed to repeat the basic hormonal tests -a test of inhibition with 1 mg dexamethasone and metanephrines excreted in the urine for the first 3-5 years after diagnosis. 9 The recom� mendations of the ESE suggest that the hormonal diagno� sis should not be repeated unless the hormonal activity of the tumor was confirmed in the first hormonal examination (cortisol in the test with 1 mg dexamethasone was less than 1.8 μg/dL). The only exception are patients who have been diagnosed with autonomous secretion of cortisol and if there are new clinical symptoms of adrenocortical hormone activ� ity (eg. hypertension or type 2 diabetes), which may arise at the different moments of follow�up. 31 Image and hormonal diagnosis are not always sufficient to diagnose and deter� mine the character of AI and repeating them increases the cost of treatment. 40
CONCLUSIONS
AI is a common clinical problem and its picture is hetero� geneous. In clinical practice, however, it appears that both imaging and hormonal tests require periodic re�indications. This significantly reduces anxiety of the patient, in addi� tion, leaving the patient in the observation allows to moni� tor the patient's condition and the appearance of symptoms of possible excessive tumor activity. 
Urgent
Oncological Endocrinological
Symptoms of tumor bleeding (risk of bleeding into the retroperitoneal space)
Tumors sized more than 4-5 cm Tumors with native density more than 10 jH in TK and/or contrast elimination less than 50% Tumors rapidly growing above 0. 
